1. The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension
- Author
-
Weber, T, Januszewicz, A, Rosei, Ea, Tsioufis, K, Okorie, M, Stergiou, Gs, Volpe, M, Kreutz, R, Abraham, G, Azizi, M, Barna, I, Barroso, Wks, Brguljan, J, Chapman, N, De Backer, T, Dorobantu, M, Eckert, S, Gaciong, Z, Giannattasio, C, Glover, M, Gottsater, A, Grassos, C, Jarai, Z, Aguila, Fj, Kahan, T, Lopez-Sublet, M, Lovic, D, Lurbe, E, Makris, Tk, Mallamaci, F, Manolis, Aj, Marketou, M, Mazza, A, Mediavilla, Jd, Muiesan, Ml, Muxfeldt, Es, Nasr, E, Papadakis, I, Parounak, Z, Obregon, S, Oliveras, A, Pontremoli, R, Raev, D, Rajkumar, C, Redon, J, Robles, Nr, Rump, Lc, Sarzani, R, Sierra, C, Sirenko, Y, Stojanov, V, Tikkanen, I, Vaclavik, J, Veglio, F, Viigimaa, M, Webb, D, Zebekakis, P, and Zweiker, R
- Subjects
medicine.medical_specialty ,Ambulatory blood pressure ,Coronavirus disease 2019 (COVID-19) ,Physiology ,media_common.quotation_subject ,Shutdown ,Angiotensin-Converting Enzyme Inhibitors ,Covid-19 ,blood pressure ,hypertension routine care ,renin-angiotensin system inhibitors ,Angiotensin Receptor Antagonists ,Antihypertensive Agents ,Blood Pressure Monitoring, Ambulatory ,COVID-19 ,Delivery of Health Care ,Europe ,Humans ,Hypertension ,Renin-Angiotensin System ,SARS-CoV-2 ,Surveys and Questionnaires ,Health Facilities ,Health Services Accessibility ,Pandemics ,Virus diseases ,Blood Pressure Monitoring ,Excellence ,Ambulatory ,Pandemic ,Internal Medicine ,Medicine ,Routine care ,media_common ,business.industry ,Blood pressure ,Emergency medicine ,angiotensin receptor antagonists ,angiotensin-converting enzyme inhibitors ,antihypertensive agents ,blood pressure monitoring ,ambulatory ,delivery of health care ,humans ,hypertension ,renin-angiotensin system ,surveys and questionnaires ,health facilities ,health services accessibility ,pandemics ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: The Covid-19 pandemic caused a shutdown of healthcare systems in many countries. We explored the impact on hypertension care in the Excellence Center (EC) network of the European Society of Hypertension. Methods: We conducted a 17-question electronic survey among ECs. Results: Overall, 52 ECs from 20 European and three non-European countries participated, providing hypertension service for a median of 1500 hypertensive patients per center per year. Eighty-five percent of the ECs reported a shutdown lasting for 9 weeks (range 0–16). The number of patients treated per week decreased by 90%: from a median of 50 (range 10–400) before the pandemic to a median of 5.0 (range 0–150) during the pandemic (P < 0.0001). 60% of patients (range 0–100%) declared limited access to medical consultations. The majority of ECs (57%) could not provide 24-h ambulatory BP monitoring, whereas a median of 63% (range 0–100%) of the patients were regularly performing home BP monitoring. In the majority (75%) of the ECs, hypertension service returned to normal after the first wave of the pandemic. In 66% of the ECs, the physicians received many questions regarding the use of renin–angiotensin system (RAS) blockers. Stopping RAS-blocker therapy (in a few patients) either by patients or physicians was reported in 27 and 36.5% of the ECs. Conclusion: Patient care in hypertension ECs was compromised during the Covid-19-related shutdown. These data highlight the necessity to develop new strategies for hypertension care including virtual clinics to maintain services during challenging times.
- Published
- 2021